WuXi PharmaTech ($WX) says it has expanded a biologics plant in Shanghai by adding two 2,000-liter disposable bioreactors. The facility already has two cell culture suites containing the 500-liter and 1,000-liter disposable bioreactors in operation. The company says with the addition, its WuXi AppTec division is operating the largest biologics facility with disposable bioreactors in China and the largest disposable bioreactor in the world. It said the company has reached an "important milestone in the global biologics manufacturing industry" with a successful run of the 2,000-liter bioreactor using an NS0 mouse myeloma cell line for TaiMed Biologics' ibalizumab, a novel CD4 entry inhibitor for treating HIV/AIDS infections. "Although there is overcapacity in biologics manufacturing facilities globally, our biologics manufacturing facility is the only one in China that meets global cGMP standards," the company said. There has been a big build-up in the last year of biologics manufacturing capacity as drugmakers and contract manufacturers prepare for the rollout of many more cell-based treatments. Announcement | More